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Abstract
Purpose A prospective randomized clinical trial was
carried out to observe the analgesic efficacy of ropivacaine
for postoperative pain following thoracolumbar spinal
surgery.
Methods Seventy-one patients with elective posterior
thoracolumbar spinal surgery were randomly divided into
two groups. Local group received 0.33 % ropivacaine by
pump through the wound, and intravenous group received
flurbiprofen axetil, pentazocine and palonosetron via in-
travenous pump. We evaluated the level of pain, the inci-
dence of adverse reactions at 2, 4, 6, 12, 24, 36 and 48 h
after operation, and the occurrence of chronic pain
3 months later.
Results There were no significant differences in the pain
level between the two groups. However, the incidence of
nausea, vomiting and chronic pain was significantly lower
in the local group.
Conclusions Our results showed that local infusion of
ropivacaine achieved similar analgesic effects to
intravenous delivery of analgesic drugs, but significantly
reduced incidence of nausea, vomiting and chronic pain.
Keywords Local analgesia  Ropivacaine  Postoperative
pain  Chronic pain  Thoracolumbar spinal surgery
Introduction
Pain is the most commonly reported symptom in primary
care after spinal surgery, while musculoskeletal pain ac-
counts for half of all reported pain complaints [1]. The
benefits of well-controlled postoperative pain include re-
duced postoperative cardiopulmonary complications, hos-
pital mortality and length of hospital stay [2]. Modern pain
control after major surgery involves a number of different
analgesic modalities. Peripheral pain control by incisional
local anesthesia is a new method in the treatment of post-
operative pain especially after various surgical procedures.
Wound infusion with local anesthetics can continuously
infiltrate the peripheral nerve endings, and attenuates pain
by directly blocking the neuronal membrane sodium
channels. A single bolus of local anesthetics in the surgical
site can provide a narcotic-limiting pain relief for 4–8 h
after operation [3]. The time-limited effect of single bolus
administration can be further improved through continuous
surgical wound infusion techniques using multi-orifice-
type catheters, positioned by the surgeon at the end of the
procedure. A systematic review [4] of randomized con-
trolled trials confirmed the benefits and safety of this
technique when applied following several severely painful
procedures, such as cardiac, thoracic and major gyneco-
logic surgery. This technique remains effective in spinal
surgery. Recently, Rushdi et al. [5] reported that the wound
was infused with a solution of ropivacaine 0.4 %,
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suggesting the potential for the use of this method in major
spinal surgery. The current study aimed to test the anal-
gesic efficacy of wound infiltration with 1 % ropivacaine
followed by an infusion of 0.33 % following thoracolum-
bar spinal surgery. Besides, we also evaluated and recorded
the long-term effects of incisional local anesthesia on in-
cidence of postoperative chronic pain and infection, com-
pared with postoperative intravenous continuous constant-
dose analgesia (ICCA).
Materials and methods
After obtaining approval from the Local Research Ethics
Committee, and written informed consent, our study in-
cluded 71 ASA I-II patients, aged 18–75 years, scheduled
for elective thoracolumbar spinal surgery since 2013 May
to 2014 February. All 71 patients were randomly assigned
to either the local (L) group (n = 35) or the intravenous
(V) group (n = 36) using a computer-generated random
number table. Exclusion criteria included: a history of
cardiopulmonary disease, coagulation and merging with
multiple injuries. One anesthesiologist was designated to
provide postoperative management.
In the L group, we used continuous wound infusion with
ropivacaine as primary analgesia. This group received an
initial wound infiltration with 6 ml 1 % ropivacaine
(100 mg; AstraZeneca AB, Sweden) and followed by
continuous infusion with 0.33 % ropivacaine via a double
lumen catheter system at a rate of 5 ml/h (Disposable
Postoperative Local Analgesia System, Beijing Heng Yuan
Tongji Medical Technology Corporation, China) for 48 h.
Patient in L group did not receive postoperative intra-
venous continuous constant-dose analgesia (ICCA) for pain
control. The V group (n = 36) relied on ICCA for post-
operative pain control involved flurbiprofen axetil 150 mg,
pentazocine 240 mg and palonosetron 0.5 mg in 100 ml
normal saline, at a rate of 2 ml/h [5]. All patients expanded
on the use of the supplementary analgesic (flurbiprofen
50 mg intravenous injection) if necessary (VAS C4).
Patients were premedicated with phenobarbital 100 mg
and atropine 0.5 mg, 30 min before the induction of
anesthesia. After baseline measurements of heart rate,
noninvasive blood pressure, respiratory rate and oxygen
saturation, each patient was preoxygenated for 3 min be-
fore induction. All patients received the target-controlled
infusion with propofol 2–3 lg/ml using the Marsh phar-
macokinetic model and remifentanil at 3–4 ng/ml using the
Minto pharmacokinetic model for induction. Following the
induction of anesthesia, cisatracurium 0.15 mg/kg was
given as an intravenous injection. After tracheal intubation,
mechanical ventilation was initiated with 100 % oxygen
and adjusted to maintain the endtidal carbon dioxide
tension between 35 and 45 mmHg. Intermittent bolus in-
jection of cisatracurium was used to maintain full muscle
relaxation. At the end of surgery, residual neuromuscular
block was reversed, if needed, with a mixture of atropine
and neostigmine. Patients were given pentazocine 60 mg
when surgery was completed prior to extubation.
Surgery
In the L group, after the spinal implant screw and rod
system were completed, the surgeon infiltrated all surgical
strata and the paraspinal muscles along the wound bilat-
erally with a solution of ropivacaine 1 % 6 ml. Then, the
surgeon inserted two multiholed catheters through an in-
troducer needle, 1–2 cm from the lower end of the incision
along the full length of the wound. The first catheter was
positioned close to the vertebral plate and under the par-
avertebral muscles (deep layer), which were immobilized
at the skin. The second catheter was positioned above the
deep fascia (superficial layer), and then it was fixed at the
skin. A suction drain was placed near the spinal instru-
mentation level, under the deep fascia and far away from
the indwelling catheter. The double catheters were imme-
diately connected to a bacterial filter through which an
elastomeric infusion pump delivered 0.33 % ropivacaine at
a rate of 5 ml/h continually until the pump was empty. The
analgesia infusion pump was commenced following sur-
gery. Recovery from anesthesia and pain management after
surgery were identical for all patients.
Outcome measures
Demographic and operation data were collected including
disease, date of birth, gender, operating time, preoperative
VAS, perioperative remifentanil and propofol doses, and
length of surgical incision.
The primary outcome was pain score at rest during the
first 48 h postoperative period using the VAS score (0 is
defined as no pain and 10 as the maximum pain). The
following variables were defined as secondary outcomes:
sedation Ramsay scores, times of rescue analgesia requests,
incidence of postoperative nausea and vomiting, antiemetic
therapy requirements and incidence of pruritus (patients
were asked about the desire to scratch). These variables
were assessed at 2, 4, 6, 12, 24, 36 and 48 h postoperatively
through a standardized questionnaire. Wound drainage at
the catheter insertion site was assessed at 24 and 48 h
postoperatively. The catheters were removed with aseptic
technique when the drainage tube was taken off at 48 h in
all patients. The surgery area was disinfected and dressed
good after removing drainage tube and catheters. The tip of
the catheters was subjected to microbiological analysis. No
patients had malfunction or by obstruction (bending, seals
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traces of blood) or fever. In case of symptoms of CNS
toxicity, such as numbness of the tongue, dizziness, visual
disturbances, metallic taste, tinnitus, muscular twitching
and dysarthria, or hemodynamic changes, the ropivacaine
infusion was immediately discontinued.
Patients were discharged when they fulfilled the fol-
lowing criteria: normal body temperature, absence of
anemia and hemodynamic impairment, absence of nausea
and vomiting, VAS B3 and independent ambulation. These
criteria were assessed every day after surgery.
Three months after operation, patients were interviewed
by an investigator. Patients were asked to answer yes/no to
the following questions: residual pain (pain, pain to non-
painful stimulus, analgesic requirements) and surgical
wound infection (and need for antibiotic therapy). Satis-
faction with analgesic technique was evaluated by a
10-point scale (0 = not satisfied, 10 = maximum
satisfaction).
Statistical analysis
Statistical analysis was performed using SPSS 16.0. Sam-
ple size calculation was based on the VAS 4 h after surgery
in the pilot study (meanV = 2.4, SDV = 0.7; meanL = 2.3,
SDL = 0.5), with margin = 0.4, 1-b = 0.80 and
a = 0.05, therefore a sample size of 20 patients in each
group was needed for testing non-inferiority. For the
postoperative nausea and vomiting incidence outcome
(PV = 20 % and PL = 0 % in pilot trial), with the same a
and b values, a sample size of 35 patients per group was
obtained.
Normally distributed continuous variables (patient
characteristics and surgical information) were compared
using two-group Student t test, whereas Mann–Whitney
test with Bonferroni correction was used for comparison of
VAS and Ramsay scores. The gender between two groups
was compared using the v2 test. The incidence of postop-
erative nausea and vomiting, pruritus, and fulfillment of
discharge criteria werer analyzed with the Fisher exact test.
Data collected at the 3-month follow-up call were analyzed
with the Mann–Whitney U test and the Fisher exact test. A
P\ 0.05 was considered to be statistically significant in all
cases except when the Bonferroni correction was per-
formed for pain and sedation, in which case a P\ 0.0071
was considered significant (this value represents 0.05 di-
vided by the number of repeated measures: 7).
Results
Overall, 94 patients were included in the study, and 23
patients were excluded after allocation (Fig. 1). All en-
rolled patients successfully completed the study and were
included in the main analysis. Demographic data and sur-
gical characteristics were not significantly different be-
tween the two groups (Table 1). No statistically significant
differences were observed between the two groups with
regard to operating time (L vs V, 251.91 ± 82.58 vs
246.39 ± 84.72 min; P = 0.95).
Postoperative VAS scores at rest were not significantly
different between two groups (Fig. 2). During the postop-
erative 2 days, rescue analgesic medications were required
14 times in the L group and 15 times in the control group.
All wound catheters were removed at 48 h postoperatively
without any complications, but microbiologic culture of
catheter tip from one patient detected Serratia marcescens.
Several secondary outcomes, except for the incidence of
postoperative nausea or vomiting (P = 0.025), did not
show any significant difference between groups (Fig. 3;
Table 2). Six patients in the V group experienced mild
postoperative nausea or vomiting and this did not require
discontinuation of the pump. No patients in the L group
reported postoperative nausea or vomiting, or obvious CNS
toxic signs of ropivacaine. No major adverse event oc-
curred in any patient. Pruritus, dizziness and wound drai-
nage in each group, and CNS symptoms of ropivacaine
intoxication in L group were not found.
The length of hospital stay and comprehensive evalua-
tion were not significantly different between the two
groups (Table 3). All patients received the same pattern of
analgesic treatment at hospital discharge and compliance
rate. At 3 months after the surgery, 3 patients (8.6 %) in L
group and 14 patients (38.9 %) in V group reported resi-
dual wound pain (P\ 0.05). One patient in L group, whose
microbiologic culture detected S. marcescens, returned to
hospital for further treatment.
Discussion
Our research revealed that pain scores at rest during the
48 h postoperative period were not significantly different
between the continuous ropivacaine wound infusion group
and the ICCA group, suggesting that the two methods could
achieve the same analgesic effect. More importantly,
compared with the ICCA group, a positive effect on light-
ening chronic pain 3 months later and reducing the inci-
dence of postoperative nausea and vomiting was existing.
In the research, we chose ropivacaine because of its
lower systemic toxicity and its shorter elimination half-life,
reducing the risk of plasma accumulation during prolonged
infusion [6]. We used in this experiment 6 ml 1 % ropi-
vacaine and followed by continuous infusion with 0.33 %
ropivacaine via a double lumen catheter system at a rate of
5 ml/h for 48 h. This does/volume chosen was base on the
reference [6].
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The optimal method of providing analgesia with con-
tinuous wound infusion with local anesthetic in spinal
surgery is still not conclusive. Variables such as the sur-
gical plane in which the catheter is placed, the length and
type of the catheter, the dose and duration of infusion still
remain undetermined. Bianconi et al. [7] used continuous
wound infusion with catheters placed between muscle
fascia and subcutaneous tissue after spinal surgery. And
they reported significant analgesic efficacy both in
reducing pain scores and opioid use. However, studies
have shown that subcutaneous infiltrations may not im-
prove postoperative pain scores, although they do have an
impact on opioid consumption [8, 9]. When compared
with subfascial injection, the deeper infiltration results in
better efficacy [10]. Therefore, we chose the above and
below the muscle fascia catheter location. In this study,
none of our catheter implantations affected wound
drainage.
Fig. 1 Flow diagram of the
different trial phases
Table 1 Demographic data of the patients enrolled in the study
L group (n = 35) V group (n = 36) Significance
Age (years) 51.91 ± 11.44 49.06 ± 11.20 ns
Sex (male/female) 19/16 19/17 ns
Disease
Lumbar fractures 8 6
Lumbar disc herniation and/or lumbar spondylolisthesis 26 27
Thoracic fractures 1 2
Thoracic disc herniation 0 1
Preoperative VAS 1.51 ± 0.66 1.64 ± 0.76 ns
Operating time (min) 251.91 ± 82.58 246.39 ± 84.72 ns
Length of surgical incision (cm) 10.37 ± 4.39 9.03 ± 3.53 ns
Perioperative remifentanil dose (mg) 3.03 ± 0.70 3.07 ± 1.01 ns
Perioperative propofol dose (mg) 2148.15 ± 477.47 2123.33 ± 710.84 ns
Data shown as mean ± SD (95 % confidence interval)
ns not significant
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Although some authors [11, 12] have concerns that
wound infiltration with local anesthetic may interfere with
wound closure and normal wound healing. Until now, there
is no definitive data on mature wound strength after wound
infusion analgesia. Hopf et al. [13] highlighted that
postoperative pain could affect the inflammatory response
and increase catecholamine release, leading to wound
perfusion and oxygenation decline. Conversely, it is pos-
sible that partial blockade of the inflammatory response in
the first phase of wound closure by wound infiltration with
local anesthetics through providing good pain control may
be beneficial and result in less fibroblast hyperplasia. As
Watanabe et al. [14] suggests, fluid infused into a wound
with saline may have an effect in decreasing the pain re-
sponse because it can dilute and wash out pain substances
such as histamine and vasoactive polypeptides.
Questions remain regarding the potential risk of wound
infection when providing analgesia with continuous wound
infusion with local anesthetic. Our microbiologic culture
results showed S. marcescens in one patient in the L group.
The reason was unknown. But since non-thorough aseptic
procedure during routine surgeries also occasionally causes
Serratia, we believe this case is not directly related to the
catheter implantation. Moreover, the wound infection rates
did not differ between the two groups (P[ 0.05), sug-
gesting that the catheter does not increase the risk of wound
infection in local anesthetic infusion patients. In a meta-
analysis by Liu et al. [4], the overall wound infection rate
was similar between catheter with local anesthetic (0.7 %)
and catheter with placebo or the no-catheter control group
(1.2 %). It was also reported that the incidence of catheter
or pump failure was 1.1 %. Although it has been reported
that the local anesthetic ropivacaine displays antimicrobial
activity [15], a study of continuous ropivacaine infusion in
the median sternotomy incision following cardiac surgery
showed high infection rates (9 %, n = 44) and this rate of
infection was not statistically different in the saline group
(0 %, n = 41) (P[ 0.05) [16]. However, a larger sample
size must be evaluated before a definitive conclusion can
be drawn about the safety of this technique.
Chronic pain is known to severely affect quality of life
and has significant economic consequences [6]. On strip-
ping of muscle attachment points and injury of soft tissue
in our research, there was an 8.6 and 38.9 % incidence of
dull pain within the local operative area independent of the
primary pain in L group and V group, respectively
(P\ 0.05). We suspect that the local anesthetic acts di-
rectly on the surgical site, cutting off the source of harmful
stimulation, this might cause the difference between two
groups. An recent experimental study on rat, mouse,
monkey and humans has suggested that a long noncoding
RNA contributes to neuropathic pain following nerve in-
jury [17]. And Attal et al. [18] in a double-blind controlled
crossover study with a 2-week washout period evaluated
the effect of lidocaine. A decrease in spontaneous pain,
mechanical dynamic allodynia, static mechanical allody-
nia, and hyperalgesia was demonstrated. It was thought that
washout of the injured site was dedicated to mitigating to
Fig. 2 VAS for pain at rest in the L group and V group at 2, 4, 6, 12,
24, 36 and 48 h after surgery. Data are reported as mean ± SD
Fig. 3 Ramsay scores for sedation in the L group and V group at 2, 4
and 6 h after surgery. At 12, 36 and 48 h, the Ramsay scores were 2.
Data are reported as mean ± SD






Nausea/vomiting 0 6 0.012
Pruritus 0 0
Dizziness 0 0
Wound exudation 0 0
Analysis with Fisher exact test
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peripheral neuropathic pain. In recent pharmaceutical de-
velopments, flurbiprofen has been introduced as a parental
drug carrier acting as a sustained-release formulation and
targeting injured tissue [6]. However, flurbiprofen was
mainly persisted retention in the blood circulation and
passively targeted to the site of injury with a highly per-
meable capillary endothelium. The transmission of pain
stimuli to the spinal cord cannot be inhibited completely by
flurbiprofen, which leads to long noncoding RNA changes,
and less effective inhibition of the incidence of chronic
pain than the local anesthetics.
In conclusion, the efficacy of continuous surgical wound
infusion with local anesthetics was tested using multiholed
catheters placed above and below the muscle fascia after
thoracolumbar spinal surgery. Our study showed that
continuous wound analgesia infusion pump could achieve
the same analgesic effect as ICCA during hospitalization
after spine surgery, while avoiding intravenous analgesic
drug-induced adverse effects such as postoperative nausea
and vomiting. More importantly, continuous surgical
wound infusion with local anesthetics is superior to ICCA
in reducing the incidence of chronic pain. Since the number
of patients in our study is small, the risk of bias cannot be
ignored when we make such conclusion. However, this
therapy could be an important component of multimodal
approaches for postoperative pain management.
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